Ken Takeshita, Kite global head of clinical development (Gilead)
Gilead’s Kite snares a landmark FDA OK on a $373,000 CAR-T therapy — which comes with bragging rights to the first true franchise op
While many of the top players in the immuno-oncology field have shifted their focus to new and better CAR-Ts in the pipeline, one of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
